Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.85 |
| ▸ | SLC10A2 | Q12908 | 5/20 | 0.35 |
| ▸ | CTSD | P07339 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919672 | 0.97 | NR1H4 (0.85) | NR1H4SLC10A2CTSD | |
| SCHEMBL5744007 | 0.96 | NR1H4 (0.92) | NR1H4SLC10A2 | |
| SCHEMBL19046549 | 0.95 | NR1H4 (0.93) | NR1H4SLC10A2CTSD | |
| SCHEMBL918882 | 0.95 | NR1H4 (0.93) | NR1H4SLC10A2CTSD | |
| SCHEMBL4566711 | 0.95 | NR1H4 (0.93) | NR1H4SLC10A2CTSD | |
| SCHEMBL25118211 | 0.95 | NR1H4 (0.85) | NR1H4SLC10A2CTSD | |
| SCHEMBL918893 | 0.95 | NR1H4 (0.85) | NR1H4SLC10A2CTSD | |
| SCHEMBL21968920 | 0.95 | NR1H4 (0.85) | NR1H4SLC10A2CTSD | |
| SCHEMBL19046596 | 0.95 | NR1H4 (0.85) | NR1H4SLC10A2CTSD | |
| SCHEMBL17772069 | 0.95 | NR1H4 (0.85) | NR1H4SLC10A2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427423-B9 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2017-12-20 | — | — | EP | disclosed |
| EP-1427423-B1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | EP | disclosed |
| US-7132416-B2 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20050038009-A1 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia | ALBIREO AB (SE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038009-A1 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia | SLC10A2, SLC10A1, ABCB11 | NR1H4 4/4885SLC10A2 1/4885CTSD 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.